These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3929601)

  • 1. Inhibition of peptic activity by sucralfate.
    Samloff IM; O'Dell C
    Am J Med; 1985 Aug; 79(2C):15-8. PubMed ID: 3929601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characteristics of sucralfate.
    Nagashima R
    J Clin Gastroenterol; 1981; 3(Suppl 2):103-10. PubMed ID: 6798099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of peptic aggression by sucralfate. The view from the ulcer crater.
    Samloff IM
    Scand J Gastroenterol Suppl; 1983; 83():7-11. PubMed ID: 6415806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sucralfate: antipeptic, antiulcer activities and antagonism of gastric emptying.
    Borella LE; Seethaler K; Lippmann W
    Arzneimittelforschung; 1979; 29(5):793-8. PubMed ID: 387045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pepsins, peptic activity, and peptic inhibitors.
    Samloff IM
    J Clin Gastroenterol; 1981; 3(Suppl 2):91-4. PubMed ID: 6119339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sucralfate and its components on acid- and pepsin-induced damage to rat gastric epithelial cells.
    Furukawa O; Matsui H; Suzuki N
    Jpn J Pharmacol; 1997 Sep; 75(1):21-5. PubMed ID: 9334882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sucralfate: development of a new concept of anti-ulcer treatment. Review of its pharmacodynamic properties].
    Gorget C
    Rev Med Interne; 1985 Jun; 6(3):313-9. PubMed ID: 3901171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro inhibition of peptic degradation of porcine gastric mucus glycoprotein by sucralfate.
    Slomiany BL; Laszewicz W; Slomiany A
    Scand J Gastroenterol; 1985 Sep; 20(7):857-60. PubMed ID: 3931205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein.
    Ito Y; Nakamura S; Onoda Y; Sugawara Y; Takaiti O
    Jpn J Pharmacol; 1993 Jun; 62(2):169-74. PubMed ID: 8371515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sucralfate protects blood clots from peptic digestion by gastric juice in vitro.
    Nysaeter G; Berstad A
    Digestion; 2006; 73(2-3):198-203. PubMed ID: 16837806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids.
    Bonten MJ; Gaillard CA; van der Geest S; van Tiel FH; Beysens AJ; Smeets HG; Stobberingh EE
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1825-34. PubMed ID: 8520743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-ulcer drug sucralfate does not affect gastric nicotine levels.
    Lindell G; Graffner H
    Eur J Clin Pharmacol; 1996; 49(6):511-3. PubMed ID: 8706778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and In vivo evaluations of a tableted antacid and sucralfate, a new antiulcer agent.
    McGraw BF; Hesterlee EJ; Lanza FL; Tesler MA
    Am J Gastroenterol; 1981 Nov; 76(5):412-5. PubMed ID: 6895973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sucralfate, a basic aluminum salt of sucrose sulfate. IV. Interaction with enzyme pepsin.
    Yoshida N; Terao N; Nagashima R
    Arzneimittelforschung; 1980; 30(1):78-80. PubMed ID: 6768370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adsorption of bile acids by sucralfate, antacids, and cholestyramine in vitro.
    Ståhlberg M; Jalovaara P; Laitinen S; Mokka R; Hentilä R; Järvensivu P; Kairaluoma M
    Clin Ther; 1987; 9(6):615-21. PubMed ID: 3440273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid neutralizing capacities and protective effect of sucralfate.
    Delchier JC; Dutreuil C; Rothman N; Soulé JC
    Dig Dis Sci; 1985 Jun; 30(6):600-1. PubMed ID: 3838929
    [No Abstract]   [Full Text] [Related]  

  • 17. Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus.
    Pearson JP; Roberts NB
    Clin Sci (Lond); 2001 Apr; 100(4):411-7. PubMed ID: 11256980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of action of sucralfate.
    Nagashima R
    J Clin Gastroenterol; 1981; 3(Suppl 2):117-27. PubMed ID: 6798100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology, clinical efficacy, and adverse effects of sucralfate, a nonsystemic agent for peptic ulcer.
    Spiro HM
    Pharmacotherapy; 1982; 2(2):67-71. PubMed ID: 6927335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of acute stress bleeding with sucralfate, antacids, or cimetidine. A controlled study with pirenzepine as a basic medication.
    Tryba M; Zevounou F; Torok M; Zenz M
    Am J Med; 1985 Aug; 79(2C):55-61. PubMed ID: 3876031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.